World first trial to improve prostate cancer care

November 28, 2013

Researchers and clinicians from the University of Sydney and the Northern Sydney Cancer Centre are leading a world first clinical trial using a tracking system to improve prostate cancer radiotherapy treatment.

The multileaf collimator (MLC) tracking system uses the Calypso system, a GPS-like device to track the position of the prostate to continuously target the tumour with sub-millimetre accuracy as it moves during therapy.

A prostate can move up to 1.5 centimetres during a radiation treatment session and in current practice the tumour is positioned before treatment, but this motion is not monitored or corrected for during treatment.

MLC is a computer-controlled device with numerous narrow slats or leaves that can be moved in and out to create apertures of different sizes. This tool is used to shape and reshape the radiotherapy treatment beam during treatment to match the three-dimensional shape of the area being targeted.

In addition to shaping the treatment beam, the MLC responds to signals from a tiny set of transponders implanted into the prostate to follow the tumour as it moves.

The trial's lead clinician Dr Tom Eade said the use of MLC tracking will potentially improve the accuracy of radiation delivery and reduce the impact on surrounding healthy tissue and sensitive structures such as the rectum and bladder.

"Royal North Shore Hospital has a history of implementing some of the most advanced radiotherapy in Australia and this is reflected in our excellent patient outcomes at the Northern Sydney Cancer Centre," he said.

"But today is the first time we will follow the tumour continuously during treatment. This breakthrough may potentially change the paradigm of treatments, opening the opportunity for patients to have their cancer cured with radiation in just 1-2 weeks of treatment with very low side effects," said Dr Eade.

University of Sydney Medical School's Professor Paul Keall said having a radiation beam continuously target the prostate means that the prostate will receive more than 98 per cent of the radiation dose planned.

"We are recording the estimated treatment improvements with MLC tracking, as well as recording the actual patient outcomes.

"Based on prior data we estimate that tumour dose misses, which can be up to 30 per cent in current practice, can be reduced to below two per cent," Professor Keall said.

The revolutionary use of MLC tracking also has the potential to reduce prostate cancer radiation therapy from an eight week program to just five days, as the greater level of accuracy could make it possible to safely deliver higher doses across fewer treatment sessions.

"This shorter course is better for patients and more cost-efficient," Dr Eade said.

Prostate cancer is the most common cancer diagnosed in Australia and the third most common cause of cancer death. It is more common in older men, with 85 per cent of cases diagnosed in men over 65 years of age.

The trial is the culmination of a 14-year research project initially started by Professor Keall. It is being supported by Varian Medical Systems to undertake the study at the Northern Sydney Cancer Centre at Royal North Shore Hospital.

Professor Keall said the team hoped the MLC tracking technology could extend to other cancers such as lung, pancreas and liver tumours in the future.

Thirty prostate patients will be the first to benefit from MLC tracking technology during this current clinical trial.

Those interested in participating in the trial can call the Northern Sydney Cancer Centre on 02 9463 1199.

Explore further: A promising step forward in prostate cancer treatment

Related Stories

A promising step forward in prostate cancer treatment

August 6, 2012
When treating prostate cancer with radiotherapy, knowing the prostate cancer position is critical to accurately targeting the radiation beam to avoid missing the tumour and irradiating healthy tissue. Prostate cancer patients ...

Scientists finally discover which prostate cancers are life-threatening

November 19, 2013
Cancer Research UK scientists have discovered that the presence of a specific protein can distinguish between prostate cancers that are aggressive and need further treatment from those that may never seriously harm the patient.

Combination therapy could lead to reduction in prostate cancer recurrence

November 14, 2013
Prostate cancer patients who receive radiotherapy could soon be treated more effectively, according to research published today in the British Journal of Cancer.

Scientists overcome barrier to prostate cancer research

October 24, 2013
Monash scientists have overcome one of the major barriers to the study and treatment of localised -or organ confined- prostate cancer.

Balloon mis-positioning during prostate cancer treatment could affect success of radiation delivery

November 12, 2013
A University of Colorado Cancer Center study recently published in the journal Physics in Medicine and Biology shows that endorectal balloons commonly used during precise radiation treatment for prostate cancer can deform ...

Oxygen levels in tumours affect response to treatment

November 7, 2013
(Medical Xpress)—The genetic make-up of a patient's tumour could be used to personalise their treatment, and help to decide whether they would benefit from receiving additional drugs as part of their radiotherapy programme, ...

Recommended for you

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.